Ropanicant

Neurological drug under development From Wikipedia, the free encyclopedia

Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and other neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects.[1] By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.

Other namesSUVN-911
CAS Number
PubChem CID
IUPHAR/BPS
Quick facts Clinical data, Other names ...
Ropanicant
Clinical data
Other namesSUVN-911
Identifiers
  • (1R,3S,5R)-3-[(6-Chloropyridin-3-yl)oxymethyl]-2-azabicyclo[3.1.0]hexane
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC11H13ClN2O
Molar mass224.69 g·mol−1
3D model (JSmol)
  • C1[C@H]2C[C@H]2N[C@@H]1COC3=CN=C(C=C3)Cl
  • InChI=S/C11H13ClN2O/c12-11-2-1-9(5-13-11)15-6-8-3-7-4-10(7)14-8/h1-2,5,7-8,10,14H,3-4,6H2/t7-,8-,10+/m0/s1
  • Key:PYSCVJMLJRHJGJ-OYNCUSHFSA-N
Close

Clinical trials

The compound has completed Phase 1 and Phase 2 clinical trials for moderate to severe major depressive disorder.[2][1] Preliminary studies have explored its potential for a faster onset of action compared to conventional antidepressants.[3] In addition to its investigation in depression, ongoing research is examining its possible use in treating neurodegenerative disorders such as Alzheimer’s disease.[4]

See also

References

Related Articles

Wikiwand AI